Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP)

Published: 2026-04-15 17:32:21 ET SVRA

Published on 04/15/2026 at 05:32 pm EDT